PET imaging in patients with brain metastasis-report of the RANO/PET group.

Brain metastases (BM) from extracranial cancer are associated with significant morbidity and mortality. Effective local treatment options are stereotactic radiotherapy, including radiosurgery or fractionated external beam radiotherapy, and surgical resection. The use of systemic treatment for intracranial disease control also is improving. BM diagnosis, treatment planning, and follow-up is most often based on contrast-enhanced magnetic resonance imaging (MRI). However, anatomic imaging modalities including standard MRI have limitations in accurately characterizing posttherapeutic reactive changes and treatment response. Molecular imaging techniques such as positron emission tomography (PET) characterize specific metabolic and cellular features of metastases, potentially providing clinically relevant information supplementing anatomic MRI. Here, the Response Assessment in Neuro-Oncology working group provides recommendations for the use of PET imaging in the clinical management of patients with BM based on evidence from studies validated by histology and/or clinical outcome.

[1]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[2]  A. Akabane,et al.  Differentiation of Brain Tumor Recurrence from Post-Radiotherapy Necrosis with 11C-Methionine PET: Visual Assessment versus Quantitative Assessment , 2015, PloS one.

[3]  R. Sweeney,et al.  PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  Gereon R. Fink,et al.  Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  J. Landsberg,et al.  Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. , 2016, Neuro-Oncology.

[6]  F. Alongi,et al.  18F-Sodium Fluoride PET-CT for the Assessment of Brain Metastasis from Lung Adenocarcinoma. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  Yang Lu FDG and (82)Rb PET/MRI features of brain metastasis of breast cancer. , 2015, Clinical nuclear medicine.

[8]  N. Shah,et al.  Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase 18F-FET PET accuracy without dynamic scans , 2017, European Radiology.

[9]  T Greitz,et al.  Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. , 1983, Journal of computer assisted tomography.

[10]  P. Brown,et al.  Brain metastases: fractionated whole-brain radiotherapy. , 2018, Handbook of clinical neurology.

[11]  Y Kanai,et al.  Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer , 2008, British Journal of Cancer.

[12]  R. Baum,et al.  Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. , 2018, The British journal of radiology.

[13]  Emily B. Ehlerding,et al.  PET Imaging of Receptor Tyrosine Kinases in Cancer , 2018, Molecular Cancer Therapeutics.

[14]  Aliasgar Moiyadi,et al.  Common malignant brain tumors: can 18F-FDG PET/CT aid in differentiation? , 2017, Nuclear medicine communications.

[15]  Gereon R. Fink,et al.  Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis , 2018, NeuroImage: Clinical.

[16]  Steven N. Kalkanis,et al.  The role of imaging in the management of progressive glioblastoma , 2014, Journal of Neuro-Oncology.

[17]  Karl-Josef Langen,et al.  Neuro-oncology: Amino acid PET for brain tumours — ready for the clinic? , 2016, Nature Reviews Neurology.

[18]  N. Sibson,et al.  Glial Activation in the Early Stages of Brain Metastasis: TSPO as a Diagnostic Biomarker , 2014, The Journal of Nuclear Medicine.

[19]  Thomas Czech,et al.  Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  N. Galldiks,et al.  From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? , 2015, Neuro-oncology.

[21]  Naoya Hashimoto,et al.  Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.

[22]  Wolfgang A. Weber,et al.  O-(2-[18F]Fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study , 2000, European Journal of Nuclear Medicine.

[23]  A. Bozzao,et al.  Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis , 2011, Radiation oncology.

[24]  K. Zilles,et al.  Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. , 2003, Nuclear medicine and biology.

[25]  N. Albert,et al.  Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  Martin Bendszus,et al.  Response assessment criteria for brain metastases: proposal from the RANO group. , 2015, The Lancet. Oncology.

[27]  Maximilian Niyazi,et al.  Prognostic Significance of Dynamic 18F-FET PET in Newly Diagnosed Astrocytic High-Grade Glioma , 2015, The Journal of Nuclear Medicine.

[28]  T. Tamiya,et al.  Correlation of l-methyl-11C-methionine (MET) uptake with l-type amino acid transporter 1 in human gliomas , 2010, Journal of Neuro-Oncology.

[29]  Whitney B Pope,et al.  Brain metastases: neuroimaging. , 2018, Handbook of clinical neurology.

[30]  N. Albert,et al.  Detection of Cerebrospinal Fluid Dissemination of Recurrent Glioblastoma Using TSPO-PET With 18F-GE-180. , 2018, Clinical nuclear medicine.

[31]  M. Weller,et al.  Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab. , 2016, Neuro-oncology.

[32]  Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study , 2013, Nuclear medicine communications.

[33]  K. Langen,et al.  Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  Val J Lowe,et al.  Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. , 2013, Neuro-oncology.

[35]  J. Mukherjee,et al.  11C-l-Methionine Positron Emission Tomography in the Clinical Management of Cerebral Gliomas , 2007, Molecular Imaging and Biology.

[36]  Rajiv Kumar,et al.  Detection of brain metastasis with 68Ga-labeled PSMA ligand PET/CT: a novel radiotracer for imaging of prostate carcinoma. , 2015, Clinical nuclear medicine.

[37]  S. Mittal,et al.  Comparison of Amino Acid Positron Emission Tomographic Radiotracers for Molecular Imaging of Primary and Metastatic Brain Tumors , 2014, Molecular imaging.

[38]  N. Galldiks,et al.  18F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis , 2017, The Journal of Nuclear Medicine.

[39]  M. Weller,et al.  Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. , 2016, Neuro-oncology.

[40]  A. Buck,et al.  68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate? , 2016, Neuro-oncology.

[41]  Wolfgang A Weber,et al.  An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. , 2011, International journal of radiation oncology, biology, physics.

[42]  Jacques Darcourt,et al.  Study of LAT1 Expression in Brain Metastases: Towards a Better Understanding of the Results of Positron Emission Tomography Using Amino Acid Tracers , 2016, PloS one.

[43]  G. Barnett,et al.  The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery , 2001, International journal of cancer.

[44]  N. Tomura,et al.  Differentiation between Treatment-Induced Necrosis and Recurrent Tumors in Patients with Metastatic Brain Tumors: Comparison among 11C-Methionine-PET, FDG-PET, MR Permeability Imaging, and MRI-ADC—Preliminary Results , 2017, American Journal of Neuroradiology.

[45]  Karl-Josef Langen,et al.  O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. , 2006, Nuclear medicine and biology.

[46]  M. Wiesmann,et al.  O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis , 2017, Neuro-oncology.

[47]  O. Belohlávek,et al.  Brain metastases after stereotactic radiosurgery using the Leksell gamma knife: can FDG PET help to differentiate radionecrosis from tumour progression? , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[48]  P Van Tassel,et al.  Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. , 2000, Radiology.

[49]  Karl-Josef Langen,et al.  Update on amino acid PET of brain tumours , 2018, Current opinion in neurology.

[50]  Fridtjof Nüsslin,et al.  “Radio-oncomics” , 2017, Strahlentherapie und Onkologie.

[51]  H. Herzog,et al.  Role of O-(2-18F-Fluoroethyl)-l-Tyrosine PET for Differentiation of Local Recurrent Brain Metastasis from Radiation Necrosis , 2012, The Journal of Nuclear Medicine.

[52]  Edward M. Hsiao,et al.  Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis , 2011, Journal of Neuro-Oncology.

[53]  N. Galldiks,et al.  Amino acid PET in neuro-oncology: applications in the clinic , 2017, Expert review of anticancer therapy.

[54]  J. Mountz,et al.  Brain tumors. , 2012, Seminars in nuclear medicine.

[55]  I. Okayasu,et al.  High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas , 2012, Journal of Clinical Pathology.

[56]  Jill S Barnholtz-Sloan,et al.  Brain metastases: epidemiology. , 2018, Handbook of clinical neurology.

[57]  R. Baum,et al.  Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for Glioma Grading: Assessment of Individual Probability of Malignancy , 2011, Clinical nuclear medicine.

[58]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[59]  Gereon R. Fink,et al.  Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy , 2016, Neuro-oncology.

[60]  K. Peck,et al.  A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. , 2016, Neuro-oncology.

[61]  Alexander Radbruch,et al.  Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) , 2017, Neuro-oncology.

[62]  Nadim Jon Shah,et al.  Advances in neuro-oncology imaging , 2017, Nature Reviews Neurology.

[63]  J. Steinbach,et al.  From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo , 2018, Oncotarget.

[64]  J. McConathy,et al.  Radiolabeled Amino Acids for Oncologic Imaging , 2013, The Journal of Nuclear Medicine.

[65]  Otto Muzik,et al.  Differentiation of Glioblastomas from Metastatic Brain Tumors by Tryptophan Uptake and Kinetic Analysis: A Positron Emission Tomographic Study with Magnetic Resonance Imaging Comparison , 2013, Molecular imaging.

[66]  A. Buck,et al.  CXCR4-directed theranostics in oncology and inflammation , 2018, Annals of Nuclear Medicine.

[67]  Gereon R Fink,et al.  The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. , 2015, Neuro-oncology.

[68]  Eudocia Q Lee,et al.  Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. , 2018, The Lancet. Oncology.

[69]  T. Wibmer,et al.  Brain metastasis in lung cancer , 2010, Nuklearmedizin.

[70]  D. Hafler,et al.  Prospects of immune checkpoint modulators in the treatment of glioblastoma , 2015, Nature Reviews Neurology.

[71]  N. Albert,et al.  Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET- PET overcome diagnostic uncertainties? , 2016, Radiation Oncology.

[72]  Ian Law,et al.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. , 2016, Neuro-oncology.

[73]  Shigeaki Higashiyama,et al.  Diagnostic Accuracy of 11C-Methionine PET for Differentiation of Recurrent Brain Tumors from Radiation Necrosis After Radiotherapy , 2008, Journal of Nuclear Medicine.

[74]  F. Mottaghy,et al.  The Use of O-(2-18F-Fluoroethyl)-l-Tyrosine PET for Treatment Management of Bevacizumab and Irinotecan in Patients with Recurrent High-Grade Glioma: A Cost-Effectiveness Analysis , 2013, The Journal of Nuclear Medicine.

[75]  Francesco Scopinaro,et al.  Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[76]  T. Tamiya,et al.  Relation of LAT1/4F2hc expression with pathological grade, proliferation and angiogenesis in human gliomas , 2012, BMC Clinical Pathology.

[77]  M. Dziuk,et al.  Brain metastases in patient with prostate cancer found in 18F-choline PET/CT. , 2015, Nuclear medicine review. Central & Eastern Europe.

[78]  P. Bartenstein,et al.  Dynamic 18F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients , 2014, The Journal of Nuclear Medicine.

[79]  Jason S. Lewis,et al.  Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab) , 2018, Scientific Reports.

[80]  K. Ohata,et al.  Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? , 2003, Journal of neurosurgery.

[81]  Uwe Haberkorn,et al.  Intra-individual comparison of ¹⁸F-FET and ¹⁸F-DOPA in PET imaging of recurrent brain tumors. , 2014, Neuro-oncology.

[82]  M Schwaiger,et al.  Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[83]  K. Takakura,et al.  Differentiation of the Radiation-Induced Necrosis and Tumor Recurrence after Gamma Knife Radiosurgery for Brain Metastases: Importance of Multi-Voxel Proton MRS , 2005, Minimally invasive neurosurgery : MIN.

[84]  Steven P. Rowe,et al.  Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications , 2018, Annals of Nuclear Medicine.

[85]  Junia C Costa,et al.  Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma. , 2015, Neuro-oncology.

[86]  M. Weller,et al.  Letter to the Editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460] , 2014, Journal of Neuro-Oncology.

[87]  Karl-Josef Langen,et al.  Cost-Effectiveness Analysis of Amino Acid PET–Guided Surgery for Supratentorial High-Grade Gliomas , 2012, The Journal of Nuclear Medicine.

[88]  J. Menten,et al.  Non-invasive grading of brain tumours using dynamic amino acid PET imaging : does it work for 11C-Methionine? , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[89]  E. Kasper,et al.  Diagnostic Accuracy of PET, SPECT, and Arterial Spin-Labeling in Differentiating Tumor Recurrence from Necrosis in Cerebral Metastasis after Stereotactic Radiosurgery , 2015, American Journal of Neuroradiology.

[90]  S. Yomo,et al.  Prospective study of 11C–methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment , 2017, BMC Cancer.

[91]  Ian Law,et al.  The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy , 2016, NeuroImage: Clinical.

[92]  Martin Sill,et al.  Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response , 2016, Clinical Cancer Research.

[93]  R. Kefford,et al.  Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases , 2016, British Journal of Cancer.

[94]  Esin Cakan,et al.  The use of 18F-FDG PET ratios in the differential diagnosis of common malignant brain tumors. , 2015, Clinical imaging.

[95]  A. Inno,et al.  18F-NaF PET/CT Imaging of Brain Metastases. , 2016, Clinical nuclear medicine.

[96]  F. Kreth,et al.  The role of surgery for brain metastases from solid tumors. , 2018, Handbook of clinical neurology.

[97]  Ricardo J. Komotar,et al.  Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality? , 2013, Journal of Neuro-Oncology.

[98]  E. Hsiao,et al.  Cerebellar Metastases From Prostate Cancer on 68Ga-PSMA PET/CT. , 2017, Clinical nuclear medicine.

[99]  M. Ahluwalia,et al.  Systemic therapy for brain metastases. , 2018, Handbook of clinical neurology.

[100]  G. Jin,et al.  Comparison of Gadolinium-enhanced MRI and 18FDG PET/PET-CT for the diagnosis of brain metastases in lung cancer patients: A meta-analysis of 5 prospective studies , 2017, Oncotarget.

[101]  R. Avery,et al.  Incidence of Brain Metastases on Follow-up 18F-FDG PET/CT Scans of Non–Small Cell Lung Cancer Patients: Should We Include the Brain? , 2017, The Journal of Nuclear Medicine Technology.

[102]  J. Mountz,et al.  Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study , 2018, Front. Oncol..

[103]  T. Lammers,et al.  Imaging Nanomedicine-Based Drug Delivery: a Review of Clinical Studies , 2018, Molecular Imaging and Biology.

[104]  J. Sarkaria,et al.  The role of LAT1 in 18F-DOPA uptake in malignant gliomas , 2012, Journal of Neuro-Oncology.

[105]  S. Steinberg,et al.  ANG1005 for breast cancer brain metastases: correlation between 18F-FLT–PET after first cycle and MRI in response assessment , 2016, Breast Cancer Research and Treatment.

[106]  M. Weller,et al.  PET imaging in patients with meningioma—report of the RANO/PET Group , 2017, Neuro-oncology.

[107]  Michael E. Phelps,et al.  18F-FDOPA PET for Differentiating Recurrent or Progressive Brain Metastatic Tumors from Late or Delayed Radiation Injury After Radiation Treatment , 2014, The Journal of Nuclear Medicine.

[108]  Keigo Endo,et al.  Transport of 3-Fluoro-l-α-Methyl-Tyrosine by Tumor-Upregulated L-Type Amino Acid Transporter 1: A Cause of the Tumor Uptake in PET , 2012, The Journal of Nuclear Medicine.

[109]  D. Fielding,et al.  Non‐small cell lung cancer brain metastasis screening in the era of positron emission tomography‐CT staging: Current practice and outcomes , 2018, Journal of medical imaging and radiation oncology.